Navigation Links
Echo Therapeutics Announces Symphony™ tCGM System Progress
Date:5/23/2011

PHILADELPHIA, May 23, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced that it has received the key components of its next generation Symphony tCGM System design.  This newly-engineered design is currently undergoing its final functionality testing.

The updated Symphony System will be ready for demonstration in the very near-term.  Importantly, it will be further tested in a final series of clinical trials shortly thereafter, replacing the prototype used in earlier clinical trials.  

This next generation design incorporates numerous technological advances required to meet market expectations for system accuracy, manufacturability and product cost.  Echo believes that upon completion of the final development work, no significant changes will be made to the Symphony tCGM System, and that the newly-engineered device will be used for sale, subject to positive clinical studies and FDA market clearance of the product.  The addressable market for needle-free, continuous wireless glucose monitoring in the hospital critical care setting exceeds $1 billion annually and the global glucose monitoring market exceeds $12 billion annually.

"We are excited to commence what we hope are the final series of modifications and testing as we move closer to our goal of a pivotal study which would form the basis of our application to the FDA for marketing clearance of the product-candidate," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "We look forward to an exciting year of development progress and validating the improvements that we have made in clinical testing."  

The Symphony tCGM System consists of Echo's proprietary Prelude SkinPrep System, with a noninvasive wireless biosensor, and a wireless monitor or a portable handheld device for needle-free, continuous monitoring of glucose levels.

About Echo TherapeuticsEcho Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.  Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems.  These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2010, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.For More Information:Patrick T. Mooney, M.D.

Media: Richard SternChairman and Chief Executive Officer

Stern & Co.(215)717-4100

(212) 888-0044Connect With Us:- Visit our website at www.echotx.com

- Follow us on Twitter at www.twitter.com/echotx

- Join us on Facebook at www.facebook.com/echotx


'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics®
2. Serina Therapeutics Awarded Patent for Its Core Polymer Drug Delivery Technology
3. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
4. Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics
5. Regency Therapeutics and Daiichi Sankyo Announce Launch and Commercial Availability of SPRIX® (ketorolac tromethamine) Nasal Spray
6. Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
7. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
8. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
9. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
10. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
11. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... "Company") (NASDAQ: UNIS ; ASX: UNS), a developer and ... for the second quarter of fiscal 2016 (three months ended December ... Financial Results for the Second Quarter of Fiscal 2016 ... the second quarter of fiscal 2016 was $4.5 million, compared to ... customers for the second quarter of fiscal 2016 were $17.8 million, ...
(Date:2/9/2016)... 2016  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced further details of three ... functional aspects of Lewy body dementia, a disease ... Two out of the three studies were recently ... later this quarter. In addition, the Company reported ...
(Date:2/9/2016)... Hearing protection devices refer to the barriers that reduce ... ear. Hearing protection devices include earplugs, uniform attenuation earplug, ... users exposed to noise levels of over 80 dB ... inserted in the ear canal to protect the ear. ... sound perception with the help of acoustic filters. Earmuffs ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... LLC to help enterprises move workloads to the cloud. Cirracore provides a ... their cloud without traversing the Internet. Transformation Solutions (TSL Partners) provides a ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), one ... ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient foundations ... , “Since our Pay It Forward program began, we are proud to have ...
(Date:2/9/2016)... ... ... On January 12, 2016 Paul McElwee, a CroppMetcalfe HVAC technician, visited a home ... any heat. Shortly after entering the home, Paul was able to identify the problem ... carbon monoxide into the home, at 2,000 parts per million in the flue. Anything ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. ... department stores, announced it has raised $176,000 to benefit the Breast Cancer Research ... Center at the University of Iowa, The Lynn Sage Cancer Research Foundation, and ...
Breaking Medicine News(10 mins):